Ron Menezes joins Almirall’s Aqua Pharmaceuticals

Amirall's US dermatology company Aqua Pharmaceuticals has appointed Ron Menezes as its new president and general manager.

Menezes joins the group from Depomed Pharmaceuticals, where he served as vice president of sales and sales operations, pain and CNS.

Prior to his role at Depomed, Menezes was at Allergan in senior roles including vice president sales and marketing, medical dermatology and he has also held positions at Abbott, Astellas and Pfizer.

Eduardo Sanchiz, chief executive officer at Almirall, said: “We are very pleased to announce the appointment of Ron Menezes as the new president and GM of Aqua Pharmaceuticals.

“Ron’s incorporation and he experience he brings in dermatology represent a clear and undeniable opportunity to further strengthen this organisation.”

Menezes will replace Ted White, who has been president and general manager of Aqua Pharmaceuticals since January 2016.

Sanchiz added: “Almirall continues to consider Aqua as a very important platform in the US market to support existing and new products.”

Aqua Pharmaceuticals was acquired by the Spanish group back in 2013 - a deal that was worth around $400m - to access the US dermatology market.